Although XIST expression was linked to therapeutic response in CRC, NSCLC, and ovarian cancer24,51,52, we failed to find a correlation between XIST and R-CHOP therapy responsiveness in DLBCL. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.